Ophthalmology, Glaucoma & Ophthalmic Preparations Resource Center
Glaucoma drug-selection tools, dry-eye treatment support, ophthalmic antibacterials, antivirals and anti-inflammatory agents, corneal and external disease, retinal and macular disease, diabetic eye disease, cataract and myopia, neuro-ophthalmology, fortified preparations, and current GlobalRPh ophthalmology research.
Clinical background
Eye disease ranges from chronic pressure control to vision-threatening emergencies
Ophthalmology includes disorders of the ocular surface, cornea, lens, optic nerve, retina, retinal vasculature, extraocular structures and visual pathways. Some conditions evolve slowly, such as primary open-angle glaucoma or cataract, while others—including acute angle closure, infectious keratitis, retinal vascular occlusion, giant cell arteritis and sudden visual loss—can require urgent specialty evaluation.
The previous GlobalRPh page already has an unusually strong glaucoma-drop library. This rebuild preserves that strength while broadening the portal to dry eye and blepharitis, ocular infection, retinal disease, diabetic retinopathy, AMD, cataract, myopia and systemic disease with ophthalmic manifestations. Medication tables remain prominent, but current AAO and FDA resources now provide a clearer verification layer while older individual pages are updated.
- Glaucoma & ocular hypertension
- Dry eye & blepharitis
- Cornea & ocular infection
- Retina, AMD & diabetic eye disease
- Cataract & refractive disease
- Myopia control
- Neuro-ophthalmology
- Ophthalmic pharmacotherapy
Glaucoma Drug Selection, Dosing & Side-Effect Tool
GlobalRPh's glaucoma selector brings prostaglandin analogs, beta blockers, alpha-2 agonists, carbonic anhydrase inhibitors, Rho-kinase inhibitors, combination products, preservative-free options and administration guidance into one interactive resource.
Dry Eye Disease Topical Options
The existing GlobalRPh dry-eye app remains useful for topical-treatment comparison, but its prescription list is still centered on Restasis, Xiidra and Lacrisert. We are preserving the tool while expanding the portal to newer FDA-approved therapies and contemporary ocular-surface care.
GlobalRPh ophthalmology apps
Four focused tools already built around glaucoma and dry-eye pharmacotherapy
These are the most distinctive resources on the current portal and remain prominent in the new design. The update roadmap below identifies where the underlying product lists and evidence need to be brought forward.
Glaucoma drug selection
Dry-eye treatment selection
Glaucoma & ocular hypertension
GlobalRPh's deepest ophthalmic pharmacology collection
The existing portal already separates the major pressure-lowering drug classes. The rebuild keeps those class pages together and adds current AAO guidance for open-angle, glaucoma-suspect and angle-closure disease.
Major glaucoma drug classes
Combination / preservative strategy
Dry eye, eyelid disease & ocular surface
Dry-eye therapy now extends well beyond artificial tears, Restasis and Xiidra
The portal now separates aqueous-deficient dry eye, evaporative/meibomian disease, preservative exposure and blepharitis so the ocular-surface workflow is easier to navigate.
GlobalRPh dry-eye resources
Newer FDA-approved therapy to incorporate
Current AAO ocular-surface guidance
Ocular infection, cornea & inflammation
Antibacterials, antivirals, corticosteroids, fortified preparations and corneal emergencies
Infectious / antimicrobial ophthalmic therapy
Inflammation / procedural medications
Current AAO cornea / conjunctivitis guidance
Retina, macula & diabetic eye disease
AMD, diabetic retinopathy, retinal vascular disease and intravitreal therapy
Retinal therapy is underrepresented on the older portal despite a large modern intravitreal-drug landscape. This section connects current AAO guidance with GlobalRPh drug monographs and retinal research.
Age-related macular degeneration
Diabetic retinopathy / DME
Retinal vascular disease / evidence
Cataract, refractive disease & myopia
Surgery, postoperative pharmacology and the changing pediatric-myopia landscape
Cataract / anterior segment
Myopia / refractive management
Dilation / cycloplegia
Neuro-ophthalmology & systemic disease
Vision as a window into vascular, inflammatory, endocrine and neurologic disease
Giant cell arteritis / acute visual risk
Pituitary / visual-field disease
Neurodegenerative / systemic crossover
Ophthalmic pharmacotherapy
Complete GlobalRPh ophthalmic drug-table library
The established drug categories from the existing page are retained in one organized section, with current glaucoma subclass pages kept nearby.
Diagnostic / procedural & anti-inflammatory
Surface / allergy / infection
GlobalRPh Ophthalmology article library
Current and established eye-health reading
The Ophthalmology category currently surfaces its newest dedicated material from 2025 and 2024, while the older portal also links valuable 2020–2023 studies. These are reorganized below by clinical relevance rather than simply by age.
2025 & technology
GlobalRPh Ophthalmology video development
Converting an empty portal section into a useful roadmap
The existing Ophthalmology page contains a “Video Section” heading but no dedicated videos. The rebuild keeps the area honest: one current GlobalRPh AI video includes Ophthalmology, and the highest-value dedicated eye topics are identified for future video development.
Existing cross-specialty video
AI's Transformative Impact on Medical Specialties
Includes an Ophthalmology segment on image-based AI, diabetic-retinopathy screening, glaucoma monitoring and related diagnostic applications.
High-value dedicated eye videos to develop
- Glaucoma drops: mechanisms, potency and systemic precautions
- Preservative-free / BAK-free eye-drop selection
- Dry eye: aqueous-deficient vs evaporative disease
- Demodex blepharitis and newer treatment
- Diabetic-retinopathy screening and intravitreal therapy
- AMD: wet disease vs geographic atrophy
- Urgent causes of sudden visual loss
- Pediatric myopia control in the modern era
Planned GlobalRPh updates
Areas we’re continuing to improve in the Ophthalmology library
GlobalRPh's glaucoma and ophthalmic-drug tables have served as practical medication references for years, while eye care has changed across glaucoma treatment, dry eye, blepharitis, myopia control, intravitreal therapy and ocular-surface safety. We plan to preserve the strongest tools while updating product availability, evidence, current guidance and clinical workflow.
Pages we plan to refresh
- Glaucoma Drug Selection Tool: this is one of our highest-priority ophthalmology updates. We plan to reconcile its 2000s–2019 reference base with the 2025 AAO glaucoma PPPs, verify current products and formulations, incorporate newer agents such as omidenepag where appropriate, and improve laser/surgical escalation context.
- Potency of Glaucoma Drops: the current ranking relies primarily on a 2016 network meta-analysis plus older package-insert data. We plan to refresh comparative IOP reduction, combination products, dosing burden, adherence, ocular-surface tolerability, preservative exposure and the limitations of cross-trial potency comparisons.
- BAK-Free / Preservative-Free Tool: we plan to verify every currently marketed preservative-free and BAK-free formulation, remove unavailable products, distinguish truly preservative-free from alternative-preservative products, and add administration/device considerations.
- Glaucoma Drug-Class Tables: prostaglandins, beta blockers, alpha agonists, carbonic-anhydrase inhibitors, ROCK inhibitors and fixed combinations will be rechecked for current formulations, generic availability, contraindications, systemic adverse effects and current labeling.
- Dry Eye Topical Options: the current app only offers Restasis, Xiidra and Lacrisert as prescription choices. We plan to add current therapies including perfluorohexyloctane/Miebo and cyclosporine 0.1%/Vevye, verify other currently marketed products, and separate evaporative, aqueous-deficient and inflammatory dry-eye phenotypes.
- Blepharitis: GlobalRPh does not currently have a dedicated modern blepharitis page. We plan to build one covering anterior/posterior blepharitis, meibomian-gland dysfunction, Demodex, lid hygiene and FDA-approved lotilaner/Xdemvy.
- Ophthalmic Antibacterials: the existing table is extensive but needs current product verification, stronger stewardship language, clearer distinction between conjunctivitis and keratitis, contact-lens risk, culture indications and avoidance of inappropriate antibiotic-steroid combinations.
- Fortified Ophthalmic Preparations: we plan to modernize concentrations, preparation/stability references, sterility and compounding safeguards, storage, beyond-use considerations, and the role of fortified antibiotics in severe corneal infection.
- Ophthalmic Antivirals: we plan to update currently marketed agents, HSV/VZV disease distinctions, epithelial versus stromal keratitis context, systemic-antiviral crossover and ophthalmology follow-up requirements.
- Ophthalmic Corticosteroids: we plan to verify current formulations and newer agents, update post-operative/inflammatory indications, and strengthen warnings around IOP elevation, infection, delayed healing and inappropriate unsupervised use.
- Ophthalmic NSAIDs: we plan to update current perioperative products, cataract-surgery use, pain/inflammation indications and corneal-safety precautions.
- Mydriatics / Cycloplegics: we plan to update current formulations, pediatric dosing/safety, anticholinergic systemic effects, angle-closure precautions and the modern role of low-dose atropine in myopia management.
- Ocular Anti-Allergy / Decongestants: we plan to distinguish true allergy treatment from cosmetic redness relief, verify current OTC/Rx products, address rebound hyperemia and avoid implying that vasoconstrictor whitening drops treat underlying disease.
- Retina / intravitreal therapy: we plan to build a dedicated GlobalRPh retinal-drug hub covering aflibercept/Eylea HD, ranibizumab, faricimab, geographic-atrophy therapies and current indications, while linking treatment choice to AAO retina guidance rather than presenting an unstructured drug list.
- Diabetic retinopathy: we plan to connect Endocrinology and Ophthalmology with screening, pregnancy, glycemic-change considerations, DME and intravitreal therapy using the current AAO PPP.
- AMD / geographic atrophy: we plan to create a dedicated page separating non-neovascular AMD, neovascular AMD and geographic atrophy, with current imaging, supplementation and intravitreal-treatment context.
- Pediatric myopia: we plan to update the older atropine article into a modern myopia-control hub incorporating optical approaches and the 2025 FDA-authorized myopia-control spectacle-lens option.
- Urgent visual-loss pathway: we plan to add a clinician-facing triage page covering giant cell arteritis, retinal detachment, retinal vascular occlusion, acute angle closure, optic neuritis, infectious keratitis, orbital disease and neurologic causes.
Current external ophthalmology guidance
Primary AAO and FDA resources
Ophthalmic products and disease-management pathways change across glaucoma, retina, ocular surface and surgery. These primary resources provide current verification while individual GlobalRPh pages are progressively refreshed.
Supporting GlobalRPh resources
Related specialties, drug data and clinical references
Related specialty portals
Medication / laboratory support
Why older ophthalmic medication pages remain accessible during the update process
Several GlobalRPh eye-drop pages remain useful as medication and administration references even though their product lists or explanatory references need updating. We are keeping those URLs active while checking current formulations, labeling, evidence, safety and professional guidance so longstanding links are not lost before replacement content is ready.
